ArticleThe Journal of adolescent health : official publication of the Society for Adolescent Medicine2025
Acceptability, Facilitators, and Barriers of Long-Acting Injectable Cabotegravir/Rilpivirine Among Youth With HIV in the United States.
Article in The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeImplementation data on long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) among adolescents and youth with HIV (AYWH) remain sparse. We aimed to evaluate the acceptability, facilitators, and barriers of LAI-CAB/RPV among AYWH in care at a specialized HIV clinic in the United States.
methodsA prospective single-center, cross-sectional survey study among AYWH aged 12-23 years. Adapting the Theoretical Framework of Acceptability and using the Consolidated Framework for Implementation Research, two separate surveys were administered to participants receiving (RCP) and not receiving (NRCP) LAI-CAB/RPV.
resultsSixty-five participants (RCP, n = 18; NRCP, n = 47; median age = 20 years (interquartile range:18-21); 87.7% African American/Black; 55.4% males) were enrolled. Most RCP (44.4%) received LAI-CAB/RPV for 6-12 months. Most NRCP received one pill (83.0%) daily (97.9%). NRCP who have not switched were happy with oral treatment (n = 11; 31.4%) or had transportation concerns for attending appointments (n = 10; 28.6%). Sixteen (45.7%) NRCP were thinking about switching to LAI-CAB/RPV. NRCP interested in switching to LAI-CAB/RPV and RCP were motivated by removal of pill burden and fatigue and the opportunity to think less about their HIV diagnosis. Most RCP (n = 17; 94.4%) found LAI-CAB/RPV to be generally acceptable with 88.9% (n = 16) endorsing wanting to be on it long-term. Eighteen (38.3%) NRCP were at least likely to switch to LAI-CAB/RPV. DISCUSSION: LAI-CAB/RPV barriers among AYWH included side effects and more frequent visits. Removal of pill burden and fatigue and thinking less about their HIV diagnosis were the main facilitators. Further studies are needed for the implementation of LAI-CAB/RPV for AYWH in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.